{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:47:46Z","timestamp":1775864866422,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood, and behavioral disturbances. Commonly used antipsychotics differ substantially in their potential to worsen motor symptoms through dopaminergic receptor blockade. Recent real-world data on the use and continuation of antipsychotic therapy in PD are lacking. The objectives of this study are to (1) examine the continuation of <jats:italic>overall<\/jats:italic> and <jats:italic>initial<\/jats:italic> antipsychotic therapy in individuals with PD and (2) determine whether continuation varies by drug dopamine receptor blocking activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cohort study using U.S. commercially insured individuals in Optum 2001\u20132019. Adults aged 40\u2009years or older with PD initiating antipsychotic therapy, with continuous insurance coverage for at least 6 months following drug initiation, were included. Exposure to pimavanserin, quetiapine, clozapine, aripiprazole, risperidone, or olanzapine was identified based on pharmacy claims. Six-month continuation of <jats:italic>overall<\/jats:italic> and <jats:italic>initial<\/jats:italic> antipsychotic therapy was estimated by time to complete discontinuation or switching to a different antipsychotic. Cox proportional hazards models evaluated factors associated with discontinuation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 38.6% of 3566 PD patients in our sample discontinued antipsychotic therapy after the first prescription, 61.4% continued with <jats:italic>overall<\/jats:italic> treatment within 6 months of initiation<jats:bold>.<\/jats:bold> Clozapine use was too rare to include in statistical analyses. <jats:italic>Overall<\/jats:italic> therapy discontinuation was more likely for those who initiated medications with known\u00a0dopamine-receptor blocking activity (adjusted hazard ratios 1.76 [95% confidence interval 1.40\u20132.20] for quetiapine, 2.15 [1.61\u20132.86] for aripiprazole, 2.12 [1.66\u20132.72] for risperidone, and 2.07 [1.60\u20132.67] for olanzapine), compared with serotonin receptor-specific pimavanserin. <jats:italic>Initial<\/jats:italic> antipsychotic therapy discontinuation also associated with greater dopamine-receptor blocking activity medication use \u2013 adjusted hazard ratios 1.57 (1.28\u20131.94), 1.88 (1.43\u20132.46), 2.00 (1.59\u20132.52) and 2.03 (1.60\u20132.58) for quetiapine, aripiprazole, risperidone, and olanzapine, respectively, compared with pimavanserin. Similar results were observed in sensitivity analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Over one-third of individuals with PD discontinued antipsychotic therapy, especially if the initial drug has greater dopamine-receptor blocking activity. Understanding the drivers of antipsychotic discontinuation, including ineffectiveness, potentially inappropriate use, clinician inertia, patient adherence and adverse effects, is needed to inform clinical management of psychosis in PD and appropriate antipsychotic use in this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02265-x","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:03:18Z","timestamp":1624521798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Low continuation of antipsychotic therapy in Parkinson disease \u2013 intolerance, ineffectiveness, or inertia?"],"prefix":"10.1186","volume":"21","author":[{"given":"Thanh Phuong","family":"Pham Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle S.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison W.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"issue":"9","key":"2265_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jagp.2019.03.002","volume":"27","author":"D Weintraub","year":"2019","unstructured":"Weintraub D, Mamikonyan E. The neuropsychiatry of Parkinson disease: a perfect storm. Am J Geriatr Psychiatry. 2019;27(9):998\u20131018. https:\/\/doi.org\/10.1016\/j.jagp.2019.03.002.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1\u20132","key":"2265_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","volume":"289","author":"G Fenelon","year":"2010","unstructured":"Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010;289(1\u20132):12\u20137. https:\/\/doi.org\/10.1016\/j.jns.2009.08.014.","journal-title":"J Neurol Sci"},{"key":"2265_CR3","doi-asserted-by":"publisher","first-page":"3256542","DOI":"10.1155\/2017\/3256542","volume":"2017","author":"RN Taddei","year":"2017","unstructured":"Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of Psychosis in Parkinson's disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons Dis. 2017;2017:3256542\u201318. https:\/\/doi.org\/10.1155\/2017\/3256542.","journal-title":"Parkinsons Dis"},{"issue":"6","key":"2265_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/YCO.0b013e3282f0f09d","volume":"20","author":"J Broadway","year":"2007","unstructured":"Broadway J, Mintzer J. The many faces of psychosis in the elderly. Curr Opin Psychiatry. 2007;20(6):551\u20138. https:\/\/doi.org\/10.1097\/YCO.0b013e3282f0f09d.","journal-title":"Curr Opin Psychiatry"},{"key":"2265_CR5","doi-asserted-by":"publisher","unstructured":"Reinhardt MM, Cohen CI. Late-life psychosis: diagnosis and treatment. Curr Psychiatry Rep. 2015;17 2:1; doi: https:\/\/doi.org\/10.1007\/s11920-014-0542-0.","DOI":"10.1007\/s11920-014-0542-0"},{"key":"2265_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.schres.2017.06.052","volume":"193","author":"M Lindgren","year":"2018","unstructured":"Lindgren M, Torniainen-Holm M, Harkanen T, Dickerson F, Yolken RH, Suvisaari J. The association between toxoplasma and the psychosis continuum in a general population setting. Schizophr Res. 2018;193:329\u201335. https:\/\/doi.org\/10.1016\/j.schres.2017.06.052.","journal-title":"Schizophr Res"},{"issue":"6","key":"2265_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.9740\/mhc.2017.11.262","volume":"7","author":"JJ Chen","year":"2017","unstructured":"Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin. 2017;7(6):262\u201370. https:\/\/doi.org\/10.9740\/mhc.2017.11.262.","journal-title":"Ment Health Clin"},{"issue":"2","key":"2265_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180\u201398. https:\/\/doi.org\/10.1002\/mds.27602.","journal-title":"Mov Disord"},{"issue":"5","key":"2265_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1017\/cjn.2017.36","volume":"44","author":"HB Rigby","year":"2017","unstructured":"Rigby HB, Rehan S, Hill-Taylor B, Matheson K, Sketris I. Antipsychotic prescribing practices in those with parkinsonism: adherence to guidelines. Can J Neurol Sci. 2017;44(5):603\u20136. https:\/\/doi.org\/10.1017\/cjn.2017.36.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"2265_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40266-012-0038-8","volume":"30","author":"N Herrmann","year":"2013","unstructured":"Herrmann N, Marras C, Fischer HD, Wang X, Anderson GM, Rochon PA. Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study. Drugs Aging. 2013;30(1):19\u201322. https:\/\/doi.org\/10.1007\/s40266-012-0038-8.","journal-title":"Drugs Aging"},{"key":"2265_CR11","doi-asserted-by":"publisher","unstructured":"Goldman JG. Neuropsychiatric Issues in Parkinson Disease. Continuum (Minneap Minn). 2016;22 4 Movement Disorders:1086\u2013103; doi: https:\/\/doi.org\/10.1212\/CON.0000000000000353.","DOI":"10.1212\/CON.0000000000000353"},{"issue":"2","key":"2265_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40266-016-0434-6","volume":"34","author":"AH Ford","year":"2017","unstructured":"Ford AH, Almeida OP. Management of Depression in patients with dementia: is pharmacological treatment justified? Drugs Aging. 2017;34(2):89\u201395. https:\/\/doi.org\/10.1007\/s40266-016-0434-6.","journal-title":"Drugs Aging"},{"issue":"5","key":"2265_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229\u201345. https:\/\/doi.org\/10.1177\/2040622316658463.","journal-title":"Ther Adv Chronic Dis"},{"key":"2265_CR14","doi-asserted-by":"publisher","unstructured":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67 4:674\u201394; doi: https:\/\/doi.org\/10.1111\/jgs.15767.","DOI":"10.1111\/jgs.15767"},{"issue":"1","key":"2265_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40501-017-0102-4","volume":"4","author":"EA Crocco","year":"2017","unstructured":"Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological Management of Anxiety Disorders in the elderly. Curr Treat Options Psychiatry. 2017;4(1):33\u201346. https:\/\/doi.org\/10.1007\/s40501-017-0102-4.","journal-title":"Curr Treat Options Psychiatry"},{"key":"2265_CR16","doi-asserted-by":"publisher","unstructured":"Sykes DA, Moore H, Stott L, Holliday N, Javitch JA, Lane JR, et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat Commun. 2017;8 1:763; doi: https:\/\/doi.org\/10.1038\/s41467-017-00716-z.","DOI":"10.1038\/s41467-017-00716-z"},{"issue":"3","key":"2265_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001;158(3):360\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.158.3.360.","journal-title":"Am J Psychiatry"},{"key":"2265_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2147\/CIA.S63942","volume":"9","author":"P Gareri","year":"2014","unstructured":"Gareri P, Segura-Garcia C, Manfredi VG, Bruni A, Ciambrone P, Cerminara G, et al. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging. 2014;9:1363\u201373. https:\/\/doi.org\/10.2147\/CIA.S63942.","journal-title":"Clin Interv Aging"},{"key":"2265_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","volume":"192","author":"S Aringhieri","year":"2018","unstructured":"Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther. 2018;192:20\u201341. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.012.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2265_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","volume":"33","author":"IM Lako","year":"2013","unstructured":"Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K. Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33(5):675\u201381. https:\/\/doi.org\/10.1097\/JCP.0b013e3182983ffa.","journal-title":"J Clin Psychopharmacol"},{"issue":"9916","key":"2265_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(13)62106-6.","journal-title":"Lancet."},{"issue":"6","key":"2265_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/JCP.0000000000000597","volume":"36","author":"HC Ndukwe","year":"2016","unstructured":"Ndukwe HC, Nishtala PS. Time-to-first discontinuation, adherence and persistence in new users of second-generation antipsychotics. J Clin Psychopharmacol. 2016;36(6):649\u201357. https:\/\/doi.org\/10.1097\/JCP.0000000000000597.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2265_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/WNF.0000000000000260","volume":"41","author":"C Stuijt","year":"2018","unstructured":"Stuijt C, Karapinar-Carkit F, van den Bemt B, van Laar T. Effect of pharmacist-led interventions on (non) motor symptoms, medication-related problems, and quality of life in Parkinson disease patients: a pilot study. Clin Neuropharmacol. 2018;41(1):14\u20139. https:\/\/doi.org\/10.1097\/WNF.0000000000000260.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"2265_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/ijcp.12439","volume":"68","author":"DJ Daley","year":"2014","unstructured":"Daley DJ, Deane KH, Gray RJ, Clark AB, Pfeil M, Sabanathan K, et al. Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial. Int J Clin Pract. 2014;68(8):963\u201371. https:\/\/doi.org\/10.1111\/ijcp.12439.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"2265_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/13607863.2013.832732","volume":"18","author":"M Azermai","year":"2014","unstructured":"Azermai M, Vander Stichele RR, Van Bortel LM, Elseviers MM. Barriers to antipsychotic discontinuation in nursing homes: an exploratory study. Aging Ment Health. 2014;18(3):346\u201353. https:\/\/doi.org\/10.1080\/13607863.2013.832732.","journal-title":"Aging Ment Health"},{"issue":"4","key":"2265_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/JGP.0b013e3182110563","volume":"20","author":"DP Devanand","year":"2012","unstructured":"Devanand DP, Mintzer J, Schultz S, Sultzer D, de la Pena D, Gupta S, et al. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012;20(4):362\u201373. https:\/\/doi.org\/10.1097\/JGP.0b013e3182110563.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2265_CR27","unstructured":"OptumTM. Real world health care experiences from over 150 million unique individuals since 1993. https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/5302_Data_Assets_Chart_Sheet_ISPOR.pdf (2015, June). Accessed."},{"key":"2265_CR28","first-page":"60","volume-title":"Current population reports","author":"JCBE Barnett","year":"2017","unstructured":"Barnett JCBE. Health insurance coverage in the United States: 2016. In: Current population reports. Washington, DC: United States Census Bureau; 2017. p. 60\u2013260."},{"key":"2265_CR29","doi-asserted-by":"publisher","first-page":"110531","DOI":"10.1016\/j.biopha.2020.110531","volume":"130","author":"CE Leonard","year":"2020","unstructured":"Leonard CE, Brensinger CM, Pham Nguyen TP, Horn JR, Chung S, Bilker WB, et al. Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. Biomed Pharmacother. 2020;130:110531. https:\/\/doi.org\/10.1016\/j.biopha.2020.110531.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2265_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138. https:\/\/doi.org\/10.1007\/s40471-015-0053-5.","journal-title":"Curr Epidemiol Rep"},{"key":"2265_CR31","unstructured":"Wermuth L, Lassen CF, Himmerslev L, Olsen J, Ritz B. Validation of hospital register-based diagnosis of Parkinson's disease. Dan Med J. 2012;59 3:A4391."},{"issue":"8","key":"2265_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/mds.20479","volume":"20","author":"K Swarztrauber","year":"2005","unstructured":"Swarztrauber K, Anau J, Peters D. Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data. Mov Disord. 2005;20(8):964\u201370. https:\/\/doi.org\/10.1002\/mds.20479.","journal-title":"Mov Disord"},{"key":"2265_CR33","doi-asserted-by":"publisher","unstructured":"Cioltan H, Alshehri S, Howe C, Lee J, Fain M, Eng H, et al. Variation in use of antipsychotic medications in nursing homes in the United States: A systematic review. BMC Geriatr. 2017;17 1:32; doi: https:\/\/doi.org\/10.1186\/s12877-017-0428-1.","DOI":"10.1186\/s12877-017-0428-1"},{"issue":"2","key":"2265_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jamda.2013.10.007","volume":"15","author":"NJ Weerkamp","year":"2014","unstructured":"Weerkamp NJ, Tissingh G, Poels PJ, Zuidema SU, Munneke M, Koopmans RT, et al. Parkinson disease in long term care facilities: a review of the literature. J Am Med Dir Assoc. 2014;15(2):90\u20134. https:\/\/doi.org\/10.1016\/j.jamda.2013.10.007.","journal-title":"J Am Med Dir Assoc"},{"issue":"7","key":"2265_CR35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749\u201359. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.10.004.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2265_CR36","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MLR.0000000000000824","volume":"55","author":"JW Sun","year":"2017","unstructured":"Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, et al. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046\u201351. https:\/\/doi.org\/10.1097\/MLR.0000000000000824.","journal-title":"Med Care"},{"issue":"7","key":"2265_CR37","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","volume":"73","author":"DH Kim","year":"2018","unstructured":"Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci. 2018;73(7):980\u20137. https:\/\/doi.org\/10.1093\/gerona\/glx229.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"2265_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1176\/appi.ps.201300118","volume":"65","author":"PR Desai","year":"2014","unstructured":"Desai PR, Adeyemi AO, Richards KM, Lawson KA. Adherence to oral diabetes medications among users and nonusers of antipsychotic medication. Psychiatr Serv. 2014;65(2):215\u201320. https:\/\/doi.org\/10.1176\/appi.ps.201300118.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"2265_CR39","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/bcp.14214","volume":"86","author":"B Roux","year":"2020","unstructured":"Roux B, Sirois C, Simard M, Gagnon ME, Laroche ML. One-year persistence of potentially inappropriate medication use in older adults: a population-based study. Br J Clin Pharmacol. 2020;86(6):1062\u201380. https:\/\/doi.org\/10.1111\/bcp.14214.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"2265_CR40","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/phar.2457","volume":"40","author":"TP Pham Nguyen","year":"2020","unstructured":"Pham Nguyen TP, Chen Y, Thibault D, Leonard CE, Hennessy S, Willis A. Impact of hospitalization and medication switching on post-discharge adherence to Oral anticoagulants in patients with atrial fibrillation. Pharmacotherapy. 2020;40(10):1022\u201335. https:\/\/doi.org\/10.1002\/phar.2457.","journal-title":"Pharmacotherapy."},{"issue":"8","key":"2265_CR41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","volume":"25","author":"LB Zahodne","year":"2008","unstructured":"Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging. 2008;25(8):665\u201382. https:\/\/doi.org\/10.2165\/00002512-200825080-00004.","journal-title":"Drugs Aging"},{"issue":"9","key":"2265_CR42","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200326090-00004","volume":"26","author":"HH Fernandez","year":"2003","unstructured":"Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf. 2003;26(9):643\u201359. https:\/\/doi.org\/10.2165\/00002018-200326090-00004.","journal-title":"Drug Saf"},{"issue":"1","key":"2265_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/mds.20260","volume":"20","author":"HH Fernandez","year":"2005","unstructured":"Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord. 2005;20(1):104\u20135. https:\/\/doi.org\/10.1002\/mds.20260.","journal-title":"Mov Disord"},{"key":"2265_CR44","doi-asserted-by":"publisher","unstructured":"Roussidis A, Kalkavoura C, Dimelis D, Theodorou A, Ioannidou I, Mellos E, et al. Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study. Ann Gen Psychiatry. 2013;12 1:42; doi: https:\/\/doi.org\/10.1186\/1744-859X-12-42.","DOI":"10.1186\/1744-859X-12-42"},{"issue":"5","key":"2265_CR45","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/s0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002;52(5):438\u201345. https:\/\/doi.org\/10.1016\/s0006-3223(02)01392-6.","journal-title":"Biol Psychiatry"},{"issue":"11","key":"2265_CR46","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1248\/bpb.b17-00602","volume":"40","author":"R Iketani","year":"2017","unstructured":"Iketani R, Kawasaki Y, Yamada H. Comparative utility of atypical antipsychotics for the treatment of psychosis in Parkinson's disease: a systematic review and Bayesian network meta-analysis. Biol Pharm Bull. 2017;40(11):1976\u201382. https:\/\/doi.org\/10.1248\/bpb.b17-00602.","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"2265_CR47","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1177\/1060028017703992","volume":"51","author":"KJ Wilby","year":"2017","unstructured":"Wilby KJ, Johnson EG, Johnson HE, Ensom MHH. Evidence-based review of pharmacotherapy used for Parkinson's disease psychosis. Ann Pharmacother. 2017;51(8):682\u201395. https:\/\/doi.org\/10.1177\/1060028017703992.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2265_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/mds.1258","volume":"17","author":"SA Factor","year":"2002","unstructured":"Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord. 2002;17(1):221\u20132. https:\/\/doi.org\/10.1002\/mds.1258.","journal-title":"Mov Disord"},{"issue":"12","key":"2265_CR49","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/mds.21091","volume":"21","author":"JH Friedman","year":"2006","unstructured":"Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006;21(12):2078\u201381. https:\/\/doi.org\/10.1002\/mds.21091.","journal-title":"Mov Disord"},{"key":"2265_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/ndt.s6411","volume":"6","author":"I Kohen","year":"2010","unstructured":"Kohen I, Lester PE, Lam S. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. Neuropsychiatr Dis Treat. 2010;6:47\u201358. https:\/\/doi.org\/10.2147\/ndt.s6411.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2265_CR51","doi-asserted-by":"publisher","unstructured":"Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56 9:1154\u201366; doi: https:\/\/doi.org\/10.1212\/wnl.56.9.1154.","DOI":"10.1212\/wnl.56.9.1154"},{"issue":"2","key":"2265_CR52","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1532-5415.2005.00566.x","volume":"54","author":"S Carson","year":"2006","unstructured":"Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc. 2006;54(2):354\u201361. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.00566.x.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2265_CR53","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/cia.s1698","volume":"2","author":"EC Hersch","year":"2007","unstructured":"Hersch EC, Falzgraf S. Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging. 2007;2(4):611\u201321. https:\/\/doi.org\/10.2147\/cia.s1698.","journal-title":"Clin Interv Aging"},{"key":"2265_CR54","doi-asserted-by":"publisher","unstructured":"Bessey LJ, Walaszek A. Management of Behavioral and Psychological Symptoms of Dementia. Curr Psychiatry Rep. 2019;21 8:66; doi: https:\/\/doi.org\/10.1007\/s11920-019-1049-5.","DOI":"10.1007\/s11920-019-1049-5"},{"key":"2265_CR55","doi-asserted-by":"publisher","unstructured":"Amara AW, Chahine LM, Videnovic A. Treatment of Sleep Dysfunction in Parkinson's Disease. Curr Treat Options Neurol. 2017;19 7:26; doi: https:\/\/doi.org\/10.1007\/s11940-017-0461-6.","DOI":"10.1007\/s11940-017-0461-6"},{"key":"2265_CR56","doi-asserted-by":"publisher","first-page":"198316","DOI":"10.1155\/2012\/198316","volume":"2012","author":"AM Bonnet","year":"2012","unstructured":"Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M. Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis. 2012;2012:198316\u20135. https:\/\/doi.org\/10.1155\/2012\/198316.","journal-title":"Parkinsons Dis."},{"issue":"Suppl 1","key":"2265_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/21556660.2019.1658307","volume":"8","author":"S Livezey","year":"2019","unstructured":"Livezey S, McCormick R, Shah NB, Choi L, DeClercq J, Zuckerman AD. Impact of specialty pharmacist integration on time to medication access for pimavanserin. J Drug Assess. 2019;8(Suppl 1):29.","journal-title":"J Drug Assess"},{"issue":"8","key":"2265_CR58","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.1230","volume":"15","author":"SE Andrade","year":"2006","unstructured":"Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565\u201374; discussion 75-7. https:\/\/doi.org\/10.1002\/pds.1230.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2265_CR59","doi-asserted-by":"publisher","unstructured":"Lee S, Xu Y, AG DAS, Martin EA, Doktorchik C, Zhang Z, et al. Unlocking the Potential of Electronic Health Records for Health Research. Int J Popul Data Sci. 2020;5 1:1123; doi: https:\/\/doi.org\/10.23889\/ijpds.v5i1.1123.","DOI":"10.23889\/ijpds.v5i1.1123"},{"issue":"6","key":"2265_CR60","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1017\/S1092852918001359","volume":"23","author":"KJ Black","year":"2018","unstructured":"Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, et al. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. CNS Spectr. 2018;23(6):402\u201313. https:\/\/doi.org\/10.1017\/S1092852918001359.","journal-title":"CNS Spectr"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02265-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02265-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02265-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:03:31Z","timestamp":1624521811000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02265-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2265"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02265-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"4 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Office of Regulatory Affairs of the University of Pennsylvania (Philadelphia, PA) granted Institutional Review Board exemption for all research studies performed using Optum\u2019s de-identified Clinformatics\u00ae Data Mart Database through the university (University of Pennsylvania\u2019s protocol #819924) and waived the need for consent to participate due to the de-identified nature of Optum data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Pham Nguyen receives support from the National Institute of Health [Grant #R01 NS099129]. Dr. Abraham receives support from the National Institute of Health [Grant #R01 NS099129] and other compensation from the Parkinson\u2019s Foundation. Dr. Weintraub receives support from the National Institutes of Health [Grant #R01 NS099129] and has also received research funding or support from Michael J. Fox Foundation for Parkinson\u2019s Research, Alzheimer\u2019s Therapeutic Research Initiative (ATRI), Alzheimer\u2019s Disease Cooperative Study (ADCS), the International Parkinson and Movement Disorder Society (IPMDS); honoraria for consultancy from Acadia, Aptinyx, Biogen, Bracket, CHDI Foundation, Clintrex LLC, Enterin, F. Hoffmann-La Roche Ltd., Ferring, Promentis, Sunovion, and Takeda; and license fee payments from the University of Pennsylvania for the QUIP and QUIP-RS. Dr. Willis receives financial support from National Institutes of Health [Grant #R01 NS099129], the Parkinson\u2019s Foundation, Acadia,\u00a0and the University of Pennsylvania. Mr. Thibault declared no competing interests for this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}